-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Non-Small Cell Lung Cancer Drug Details: ORM-5029 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CFI-402411 in Merkel Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CFI-402411 in Merkel Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CFI-402411 in Merkel Cell Carcinoma Drug Details: CFI-402411 is under development...
-
Product Insights
NewNon-Rhabdomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Non-Rhabdomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Non-rhabdomyosarcoma refers to a group of cancers that are distinct from rhabdomyosarcoma, a type of soft tissue cancer that arises from skeletal muscle cells. Non-rhabdomyosarcoma includes various types of soft tissue sarcomas that originate in tissues such as nerves, blood vessels, fat, and connective tissues. These sarcomas can occur in different parts of the body, and their characteristics and treatment approaches vary. Common...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986415 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986415 in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986415 in Melanoma Drug Details: BMS-986415 (DF-6002) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UI-058 in Reflux Esophagitis (Gastroesophageal Reflux Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UI-058 in Reflux Esophagitis (Gastroesophageal Reflux Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.UI-058 in Reflux Esophagitis (Gastroesophageal Reflux Disease) Drug Details:UI-058 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Desvenlafaxine Succinate Er in Depression
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Desvenlafaxine Succinate Er in Depression report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Desvenlafaxine Succinate Er in Depression Drug Details:Desvenlafaxine succinate is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CUG-252 in Inflammatory Bowel Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CUG-252 in Inflammatory Bowel Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CUG-252 in Inflammatory Bowel Disease Drug Details: CUG-252 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – C-106 in Pulmonary Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - C-106 in Pulmonary Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.C-106 in Pulmonary Hypertension Drug Details:C-106 is under development for the treatment of...